Literature DB >> 7994908

Suppression of experimental systemic lupus erythematosus (SLE) with specific anti-idiotypic antibody-saporin conjugate.

M Blank1, J Manosroi, Y Tomer, A Manosroi, J Kopolovic, S Charcon-Polak, Y Shoenfeld.   

Abstract

The importance of the idiotypic network is represented in experimental SLE induced by active immunization of naive mice with an anti-DNA idiotype (Ab1) emulsified in adjuvant. The mice after 4 months of incubation generate Ab3 having anti-DNA activity. In addition, the mice develop other serological markers for SLE associated with clinical and histopathological manifestations characteristic of the disease. To confirm further the etiological role of the idiotype in this experimental model, the mice were treated with specific anti-idiotypic antibodies (anti-Id) which were also conjugated to a toxin-saporin (Immunotoxin (IT)). Pretreatment of hybridoma cell line producing the anti-anti-Id (anti-DNA = (Ab3)) for 48 h with the anti-Id MoAb (Ab2) reduced the production of anti-DNA by 58%, while pretreatment with the IT resulted in 86% decrease in anti-DNA secretion (saporin alone had only 12% effect). The anti-Id MoAb had no effect on the production of immunoglobulin by an unrelated cell line. In vivo treatment of mice with experimental SLE led to a significant decrease in titres of serum autoantibodies, with diminished clinical manifestations. The results were more remarkable when the IT was employed. These suppressive effects were specific, since an anti-Id treatment of experimental anti-phospholipid syndrome was of no avail. The anti-Id effect was mediated via a reduction in specific anti-DNA antibody-forming cells, and lasted only while anti-Id injections were given. Discontinuation of the anti-Id injection was followed by a rise in titres of anti-DNA antibodies. No immunological escape of new anti-DNA Ids was noted. Our results point to the importance of pathogenic idiotypes in SLE and to the specific potential of implementing anti-idiotypic therapy, enhanced by the conjugation of the anti-Id to an immunotoxin, in particular one with low spontaneous toxicity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7994908      PMCID: PMC1534502          DOI: 10.1111/j.1365-2249.1994.tb05509.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  39 in total

1.  In vitro manipulation of human anti-DNA antibody production by anti-idiotypic antibodies conjugated with neocarzinostatin.

Authors:  T Sasaki; E Tamate; T Muryoi; O Takai; K Yoshinaga
Journal:  J Immunol       Date:  1989-02-15       Impact factor: 5.422

Review 2.  Current concepts: immunology. Idiotypes and idiotypic networks.

Authors:  S Burdette; R S Schwartz
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

3.  Detection of native and denatured DNA antibody forming cells by the enzyme-linked immunospot assay. A clinical study of (New Zealand black x New Zealand white)F1 mice.

Authors:  D G Ando; F M Ebling; B H Hahn
Journal:  Arthritis Rheum       Date:  1986-09

Review 4.  Immunotoxins.

Authors:  I Pastan; M C Willingham; D J FitzGerald
Journal:  Cell       Date:  1986-12-05       Impact factor: 41.582

5.  Selective elimination of anti-DNA antibody-producing cells by antiidiotypic antibody conjugated with neocarzinostatin.

Authors:  T Sasaki; T Muryoi; O Takai; E Tamate; Y Ono; Y Koide; N Ishida; K Yoshinaga
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

6.  Suppression of anti-DNA antibody synthesis in vitro by a cross-reactive antiidiotypic antibody.

Authors:  A Epstein; M Greenberg; B Diamond; A I Grayzel
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

7.  Suppression of development of experimental autoimmune myasthenia gravis with isogeneic monoclonal anti-idiotopic antibody.

Authors:  M A Agius; D P Richman
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

8.  Human monoclonal antibodies derived from pleural effusion lymphocytes of a patient with breast carcinoma react with human breast cancer-associated antigens and mouse mammary tumor virus polypeptides.

Authors:  N I Smorodinsky; S Argov; Y Ghendles; R Bakimer; M Krup; R Lupu; I Keydar; Y Shoenfeld
Journal:  Exp Cell Biol       Date:  1987

9.  Induction of a systemic lupus erythematosus-like disease in mice by a common human anti-DNA idiotype.

Authors:  S Mendlovic; S Brocke; Y Shoenfeld; M Ben-Bassat; A Meshorer; R Bakimer; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

10.  Treatment of murine lupus with F(ab')2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion.

Authors:  N L Carteron; C L Schimenti; D Wofsy
Journal:  J Immunol       Date:  1989-03-01       Impact factor: 5.422

View more
  6 in total

Review 1.  Protective role of anti-idiotypic antibodies in autoimmunity--lessons for type 1 diabetes.

Authors:  Christiane S Hampe
Journal:  Autoimmunity       Date:  2012-02-23       Impact factor: 2.815

Review 2.  Toward molecular targeting with specific intravenous immunoglobulin preparation.

Authors:  Miri Blank; Israel Nur; Orgad Toub; Anabel Maor; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 3.  New methods of treatment in an experimental murine model of systemic lupus erythematosus induced by idiotypic manipulation.

Authors:  Y Shoenfeld; I Krause; M Blank
Journal:  Ann Rheum Dis       Date:  1997-01       Impact factor: 19.103

4.  Anti-idiotype immunomodulation of experimental anti-phospholipid syndrome via effect on Th1/Th2 expression.

Authors:  I Krause; M Blank; Y Levi; T Koike; V Barak; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

5.  B Cell in Autoimmune Diseases.

Authors:  Christiane S Hampe
Journal:  Scientifica (Cairo)       Date:  2012

Review 6.  Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.

Authors:  Roger Gilabert-Oriol; Alexander Weng; Benedicta von Mallinckrodt; Matthias F Melzig; Hendrik Fuchs; Mayank Thakur
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.